Gilead reports more Phase III Adefovir data

GILD said that in subset of 130 post-liver transplant, lamivudine-resistant chronic hepatitis B virus (HBV) patients in an international 230-patient Phase III trial, 10 mg of its Adefovir oral nucleot...